![]()
|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Papers In Press, published online ahead of print October 12, 2000
J. Biol. Chem, 10.1074/jbc.M007504200
Submitted on August 17, 2000
Revised on October 12, 2000
Accepted on October 12, 2000
-phaseolin promoter by phosphatase or protein synthesis inhibitors
Institute of Developmental and Molecular Biology, Texas A&M University, College Station, TX 77843-3155
Corresponding Author: tim{at}idmb.tamu.edu
The promoter for the phaseolin (phas) bean seed protein gene adopts an inactive chromatin structure in leaves of transgenic tobacco. This repressive architecture, which confers stringent spatial regulation, is disrupted upon transcriptional activation during embryogenesis in a process that requires the presence of both a transcription factor (PvALF) and abscisic acid (ABA). Towards determining the need for de novo synthesis of proteins other than PvALF in transcriptional activation we explored the effect of several eukaryotic protein synthesis inhibitors. Surprisingly, cycloheximide (CHX), emetine and verrucarin A were able to induce transcription from the phas promoter in tobacco and bean leaf tissue in the absence of either PvALF or ABA. This induction was decreased by the replication inhibitors aphidicolin and hydroxyurea, but not by genestein or mimosine. Since protein phosphatases and kinases are essential components of the ABA signal transduction pathway it is conceivable that CHX is also capable of inducing phosphorylation of proteins usually involved in ABA-mediated activation. Interestingly, okadaic acid, an inhibitor of serine/threonine phosphatase, also strongly activated transcription from the phas promoter. In contrast, the protein synthesis inhibitors anisomycin and puromycin did not activate transcription from the phas promoter, nor did the tyrosine phosphatase inhibitors phenylarsine oxide and sodium orthovanadate. These discrete but different results on transcriptional activation may reflect specific modes of action of the inhibitors, or it may reflect differential interactions of the inhibitors or of downstream events resulting from inhibitor activity with presently unknown components of the transcriptional activation system.
This article has been cited by other articles:
![]() |
M. B. Chandrasekharan, G. Li, K. J. Bishop, and T. C. Hall S Phase Progression Is Required for Transcriptional Activation of the {beta}-Phaseolin Promoter J. Biol. Chem., November 14, 2003; 278(46): 45397 - 45405. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |